Amgen announced positive first quarter 2025 financial results, citing strong global demand across its product portfolio and successful new product launches.
Amgen disclosed during Q4 earnings that the FDA has placed their obesity drug AMG 513 clinical trial on hold, though executives believe the issue is not related to the medication itself.
The FDA has imposed a clinical hold on Amgen's early-stage obesity drug candidate AMG 513, potentially delaying the company's entry into the competitive weight loss market.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.